These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39021571)

  • 41. Vedolizumab for pediatric patients with gastrointestinal acute graft-versus-host-disease.
    Aldouby Bier G; Zaidman I; Dinur Schejter Y; NaserEddin A; Stepensky P; Even-Or E
    Pediatr Blood Cancer; 2023 Jan; 70(1):e30061. PubMed ID: 36326084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
    Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
    Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
    Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
    Front Immunol; 2022; 13():954268. PubMed ID: 35990629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.
    Li AC; Dong C; Tay ST; Ananthakrishnan A; Ma KS
    Front Immunol; 2022; 13():1025350. PubMed ID: 36439135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease.
    Zu Y; Gui R; Li Z; Wang J; Li P; Liu Y; Dong X; Zhou J
    Ther Adv Hematol; 2024; 15():20406207241276982. PubMed ID: 39247427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience.
    Fujioka M; Itonaga H; Furumoto T; Kasai S; Sakamoto H; Kitanosono H; Kato T; Horai M; Sato S; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
    Transpl Immunol; 2021 Aug; 67():101417. PubMed ID: 34058354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial.
    Zhao Y; Li X; Zhou Y; Gao J; Jiao Y; Zhu B; Wu D; Qi X
    Front Immunol; 2021; 12():678476. PubMed ID: 34220825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
    Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
    Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basiliximab treatment.
    Cheng C; Deng DX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Huang XJ; Mo XD
    Front Oncol; 2024; 14():1390438. PubMed ID: 38595816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study.
    Chen T; Li J; Wei X; Yao H; Zhu L; Liu J; Liu Y; Wang P; Feng Y; Gao S; Liu H; Wang L; Zhao L; Gao L; Zhang C; Gao L; Zhang X; Kong P
    Acta Haematol; 2024; 147(5):499-510. PubMed ID: 38232716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion.
    Qi L; Huang X; He C; Ji D; Li F
    J Int Med Res; 2021 Dec; 49(12):3000605211063292. PubMed ID: 34918995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients.
    Grabner M; Strati E; Sandman K; Forsythe A
    J Manag Care Spec Pharm; 2021 May; 27(5):607-614. PubMed ID: 33908282
    [No Abstract]   [Full Text] [Related]  

  • 58. Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.
    Luo C; Huang X; Wei L; Wu G; Huang Y; Ding Y; Huang Z; Chen J; Li X; Zou Y; Xu S
    Front Immunol; 2023; 14():1211171. PubMed ID: 37409129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
    Cao XY; Chen JQ; Wang H; Ma W; Liu WW; Zhang FF; Xue S; Dong L; Liu T; Zhao XZ; Liu CC; Xu X; He Y; Wang L; Wang JL
    Ann Med; 2023 Dec; 55(1):388-400. PubMed ID: 36629738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Wang J; Zhao J; Fei X; Yin Y; Cheng H; Zhang W; Gu J; Yang F; Yang Y; Xue S; Tian Z; He J; Zhang S; Wang X
    Medicine (Baltimore); 2018 Apr; 97(17):e0228. PubMed ID: 29702970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.